Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

BioMarin's Cerliponase Alfa Data Support Mid-Year Submissions

This article was originally published in Scrip

Executive Summary

BioMarin Pharmaceutical Inc.'s cerliponase alfa (BMN 190) significantly slowed the rate of neurodegenerative decline for young patients with CLN2, a form of Batten disease, compared with historical controls in a Phase I/II clinical trial, supporting plans to seek US and EU regulatory approvals within the next few months.

Advertisement

Related Content

Keeping Track: Breakthroughs Dominate 2017 Novel Agents; US FDA Approves Rydapt, Alunbrig, Tymlos, Brineura
10 Approvals To Watch For In Early 2017
Pfizer's Medivation Buyout: One-Off Deal Or Start Of A Biopharma Spending Spree?
Keeping Track: FDA Approves Adlyxin, Accepts Brineura, Lowers Hurdle For Xadago

Topics

Advertisement
UsernamePublicRestriction

Register

SC064663

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel